Cargando…

High-dose budesonide for early COVID-19

Detalles Bibliográficos
Autores principales:	Berezowski, Ivan, Patel, Jigar, Shaw, Mariame, Pourmand, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660056/ https://www.ncbi.nlm.nih.gov/pubmed/34895527 http://dx.doi.org/10.1016/S0140-6736(21)02441-7

Ejemplares similares

Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021)

High-dose budesonide for early COVID-19
por: Lipworth, Brian, et al.
Publicado: (2021)

High-dose budesonide for early COVID-19 – Authors' reply
por: Hobbs, F D Richard, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: Choi, Jae Chol, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: San-Juan, Rafael, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: Zeitlinger, Markus, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19 – Authors' reply
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Budesonide/formoterol combination for reducing cough in COVID-19 patients—A case of inflated expectations!
por: Kaur, Onkardeep, et al.
Publicado: (2023)

Budesonide: A promising candidate therapeutic for early COVID-19
por: Patel, Shailesh Kumar, et al.
Publicado: (2021)

COVID-19: could CT provide the best population level biomarker? Incidental COVID-19 in major trauma patients suggests higher than predicted rates of infection in London
por: Alhashmi, A., et al.
Publicado: (2021)

Novaferon, treatment in COVID-19 patients
por: Janapala, Rajesh Naidu, et al.
Publicado: (2021)

Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
por: Janapala, Rajesh Naidu, et al.
Publicado: (2021)

Attitudes among healthcare professionals towards cardiopulmonary resuscitation during COVID-19
por: AL-shiakh, Safinaz, et al.
Publicado: (2022)

Organizational characteristics: Effect on outcome of ICU COVID-19 patients in Belgium
por: Patel, Jigar, et al.
Publicado: (2021)

High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia
por: Nadeem, Rashid, et al.
Publicado: (2021)

COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
por: Paez Vargas, Juan José, et al.
Publicado: (2021)

Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
por: Janapala, Rajesh Naidu, et al.
Publicado: (2021)

Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
por: Agusti, Alvar, et al.
Publicado: (2021)

Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19?
por: Kareemi, Hashim, et al.
Publicado: (2021)

The Low Yield of SARS-CoV-2 Rapid Antigen Testing in Screening Asymptomatic Hospital Visitors in Low-incidence Settings
por: Boddeti, Nymisha L., et al.
Publicado: (2022)

Early triple antiviral therapy for COVID-19 – Authors' reply
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2020)

Standard Dose Ivermectin for COVID-19
por: Buonfrate, Dora, et al.
Publicado: (2021)

High Uptake of Three COVID-19 Vaccine Doses Among Liver Transplant Recipients
por: Schell, Trevor L., et al.
Publicado: (2023)

VITT and Second Doses of Covid-19 Vaccine
por: Lacy, Joanne, et al.
Publicado: (2021)

Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment
por: Jenkins, Christine R., et al.
Publicado: (2017)

Oral dexamethasone for COVID-19 patients at the initial recognition of hypoxia: Can an early dose herald a better outcome?
por: Lo, Ching-Lung, et al.
Publicado: (2022)

Inhalatives Budesonid zur Therapie bei COVID-19
por: Kluge, S., et al.
Publicado: (2021)

Tocilizumab in COVID-19: finding the optimal route and dose
por: Jain, Siddharth, et al.
Publicado: (2020)

Penile Pyoderma Gangrenosum: A Mimicker to Know
por: Mehdi, Khallaayoune, et al.
Publicado: (2021)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen
por: Pareek, Anil, et al.
Publicado: (2020)

Potential therapeutic role of budesonide to reduce COVID-19 severity
por: Mohiuddin, Md, et al.
Publicado: (2022)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing
por: Lewis, Joseph M., et al.
Publicado: (2016)

Severe Hypoxemia in Early COVID-19 Pneumonia
por: Bhatia, Pradeep, et al.
Publicado: (2020)

Early triple antiviral therapy for COVID-19
por: Lee, Nelson, et al.
Publicado: (2020)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
por: Hanania, Nicola A., et al.
Publicado: (2020)

Association between high serum total cortisol concentrations and mortality from COVID-19
por: Tan, Tricia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2nhrugnnn219mm88t0ovntrvjd